Clinical Trial Update: Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study [Phase 1, Phase 2]

View source ↗

Summary

A single-patient, phase 1/2 clinical trial is exploring base editing of hematopoietic stem cells and T cells to treat CD40L-HyperIgM Syndrome and is currently r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyper-igm Syndrome

Drugs mentioned

• Base-editing hematopoietic stem cell and T cell gene therapy for CD40L-HyperIgM Syndrome

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: CD40L-HyperIgM Syndrome | Phase 1, Phase 2 | Status: RECRUITING